FDA approves Shire's Vyvanse for ADHD

02/24/2007 | MSNBC

Shire PLC says the amphetamine-based drug is meant to supplant its top-selling Adderall XR when that drug goes off patent in 2009. Shire says it believes a new formulation, which makes the drug inactive unless swallowed, will curtail potential abuse of the drug.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ